Literature DB >> 27920622

Neoadjuvant Treatment of Breast Cancer - Advances and Limitations.

Peter A Fasching1, Paul Gaß1, Alexander Hein1.   

Abstract

Year:  2016        PMID: 27920622      PMCID: PMC5123028          DOI: 10.1159/000452463

Source DB:  PubMed          Journal:  Breast Care (Basel)        ISSN: 1661-3791            Impact factor:   2.860


× No keyword cloud information.
  12 in total

1.  Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: an update.

Authors:  Manfred Kaufmann; Gabriel N Hortobagyi; Aron Goldhirsch; Suzy Scholl; Andreas Makris; Pinuccia Valagussa; Jens-Uwe Blohmer; Wolfgang Eiermann; Raimund Jackesz; Walter Jonat; Annette Lebeau; Sibylle Loibl; William Miller; Sigfried Seeber; Vladimir Semiglazov; Roy Smith; Rainer Souchon; Vered Stearns; Michael Untch; Gunter von Minckwitz
Journal:  J Clin Oncol       Date:  2006-04-20       Impact factor: 44.544

2.  Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes.

Authors:  Gunter von Minckwitz; Michael Untch; Jens-Uwe Blohmer; Serban D Costa; Holger Eidtmann; Peter A Fasching; Bernd Gerber; Wolfgang Eiermann; Jörn Hilfrich; Jens Huober; Christian Jackisch; Manfred Kaufmann; Gottfried E Konecny; Carsten Denkert; Valentina Nekljudova; Keyur Mehta; Sibylle Loibl
Journal:  J Clin Oncol       Date:  2012-04-16       Impact factor: 44.544

3.  Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial.

Authors:  Gunter von Minckwitz; Andreas Schneeweiss; Sibylle Loibl; Christoph Salat; Carsten Denkert; Mahdi Rezai; Jens U Blohmer; Christian Jackisch; Stefan Paepke; Bernd Gerber; Dirk M Zahm; Sherko Kümmel; Holger Eidtmann; Peter Klare; Jens Huober; Serban Costa; Hans Tesch; Claus Hanusch; Jörn Hilfrich; Fariba Khandan; Peter A Fasching; Bruno V Sinn; Knut Engels; Keyur Mehta; Valentina Nekljudova; Michael Untch
Journal:  Lancet Oncol       Date:  2014-04-30       Impact factor: 41.316

4.  5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial.

Authors:  Luca Gianni; Tadeusz Pienkowski; Young-Hyuck Im; Ling-Ming Tseng; Mei-Ching Liu; Ana Lluch; Elżbieta Starosławska; Juan de la Haba-Rodriguez; Seock-Ah Im; Jose Luiz Pedrini; Brigitte Poirier; Paolo Morandi; Vladimir Semiglazov; Vichien Srimuninnimit; Giulia Valeria Bianchi; Domenico Magazzù; Virginia McNally; Hannah Douthwaite; Graham Ross; Pinuccia Valagussa
Journal:  Lancet Oncol       Date:  2016-05-11       Impact factor: 41.316

5.  Nab-paclitaxel versus solvent-based paclitaxel in neoadjuvant chemotherapy for early breast cancer (GeparSepto-GBG 69): a randomised, phase 3 trial.

Authors:  Michael Untch; Christian Jackisch; Andreas Schneeweiss; Bettina Conrad; Bahriye Aktas; Carsten Denkert; Holger Eidtmann; Hermann Wiebringhaus; Sherko Kümmel; Jörn Hilfrich; Mathias Warm; Stefan Paepke; Marianne Just; Claus Hanusch; John Hackmann; Jens-Uwe Blohmer; Michael Clemens; Silvia Darb-Esfahani; Wolfgang Daniel Schmitt; Serban Dan Costa; Bernd Gerber; Knut Engels; Valentina Nekljudova; Sibylle Loibl; Gunter von Minckwitz
Journal:  Lancet Oncol       Date:  2016-02-08       Impact factor: 41.316

6.  70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer.

Authors:  Fatima Cardoso; Laura J van't Veer; Jan Bogaerts; Leen Slaets; Giuseppe Viale; Suzette Delaloge; Jean-Yves Pierga; Etienne Brain; Sylvain Causeret; Mauro DeLorenzi; Annuska M Glas; Vassilis Golfinopoulos; Theodora Goulioti; Susan Knox; Erika Matos; Bart Meulemans; Peter A Neijenhuis; Ulrike Nitz; Rodolfo Passalacqua; Peter Ravdin; Isabel T Rubio; Mahasti Saghatchian; Tineke J Smilde; Christos Sotiriou; Lisette Stork; Carolyn Straehle; Geraldine Thomas; Alastair M Thompson; Jacobus M van der Hoeven; Peter Vuylsteke; René Bernards; Konstantinos Tryfonidis; Emiel Rutgers; Martine Piccart
Journal:  N Engl J Med       Date:  2016-08-25       Impact factor: 91.245

Review 7.  Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis.

Authors:  Patricia Cortazar; Lijun Zhang; Michael Untch; Keyur Mehta; Joseph P Costantino; Norman Wolmark; Hervé Bonnefoi; David Cameron; Luca Gianni; Pinuccia Valagussa; Sandra M Swain; Tatiana Prowell; Sibylle Loibl; D Lawrence Wickerham; Jan Bogaerts; Jose Baselga; Charles Perou; Gideon Blumenthal; Jens Blohmer; Eleftherios P Mamounas; Jonas Bergh; Vladimir Semiglazov; Robert Justice; Holger Eidtmann; Soonmyung Paik; Martine Piccart; Rajeshwari Sridhara; Peter A Fasching; Leen Slaets; Shenghui Tang; Bernd Gerber; Charles E Geyer; Richard Pazdur; Nina Ditsch; Priya Rastogi; Wolfgang Eiermann; Gunter von Minckwitz
Journal:  Lancet       Date:  2014-02-14       Impact factor: 79.321

8.  Ki67 measured after neoadjuvant chemotherapy for primary breast cancer.

Authors:  Gunter von Minckwitz; Wolfgang D Schmitt; Sibylle Loibl; Berit M Müller; Jens U Blohmer; Bruno V Sinn; Holger Eidtmann; Wolfgang Eiermann; Bernd Gerber; Hans Tesch; Jörn Hilfrich; Jens Huober; Tanja Fehm; Jana Barinoff; Thomas Rüdiger; Erhard Erbstoesser; Peter A Fasching; Thomas Karn; Volkmar Müller; Christian Jackisch; Carsten Denkert
Journal:  Clin Cancer Res       Date:  2013-06-27       Impact factor: 12.531

9.  Neo-adjuvant doxorubicin and cyclophosphamide followed by paclitaxel in triple-negative breast cancer among BRCA1 mutation carriers and non-carriers.

Authors:  Shani Paluch-Shimon; Eitan Friedman; Raanan Berger; Moshe Papa; Maya Dadiani; Neil Friedman; Moshe Shabtai; Dov Zippel; Mordechai Gutman; Talia Golan; Ady Yosepovich; Raphael Catane; Tami Modiano; Bella Kaufman
Journal:  Breast Cancer Res Treat       Date:  2016-04-25       Impact factor: 4.872

10.  PIK3CA mutations are associated with lower rates of pathologic complete response to anti-human epidermal growth factor receptor 2 (her2) therapy in primary HER2-overexpressing breast cancer.

Authors:  Sibylle Loibl; Gunter von Minckwitz; Andreas Schneeweiss; Stefan Paepke; Annika Lehmann; Mahdi Rezai; Dirk M Zahm; Peter Sinn; Fariba Khandan; Holger Eidtmann; Karel Dohnal; Clemens Heinrichs; Jens Huober; Berit Pfitzner; Peter A Fasching; Fabrice Andre; Judith L Lindner; Christos Sotiriou; August Dykgers; Sanxing Guo; Stephan Gade; Valentina Nekljudova; Sherene Loi; Michael Untch; Carsten Denkert
Journal:  J Clin Oncol       Date:  2014-09-08       Impact factor: 44.544

View more
  2 in total

1.  Update Breast Cancer 2019 Part 4 - Diagnostic and Therapeutic Challenges of New, Personalised Therapies for Patients with Early Breast Cancer.

Authors:  Florian Schütz; Peter A Fasching; Manfred Welslau; Andreas D Hartkopf; Achim Wöckel; Michael P Lux; Wolfgang Janni; Johannes Ettl; Diana Lüftner; Erik Belleville; Hans-Christian Kolberg; Friedrich Overkamp; Florin-Andrei Taran; Sara Y Brucker; Markus Wallwiener; Hans Tesch; Tanja N Fehm; Andreas Schneeweiss; Volkmar Müller
Journal:  Geburtshilfe Frauenheilkd       Date:  2019-10-22       Impact factor: 2.915

2.  Predicting dynamic response to neoadjuvant chemotherapy in breast cancer: a novel metabolomics approach.

Authors:  Caridad Díaz; Carmen González-Olmedo; Leticia Díaz-Beltrán; José Camacho; Patricia Mena García; Ariadna Martín-Blázquez; Mónica Fernández-Navarro; Ana Laura Ortega-Granados; Fernando Gálvez-Montosa; Juan Antonio Marchal; Francisca Vicente; José Pérez Del Palacio; Pedro Sánchez-Rovira
Journal:  Mol Oncol       Date:  2022-04-14       Impact factor: 7.449

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.